GB8504099D0
(en)
|
1985-02-18 |
1985-03-20 |
Wellcome Found |
Physiologically active substances
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
GB8610551D0
(en)
|
1986-04-30 |
1986-06-04 |
Hoffmann La Roche |
Polypeptide & protein derivatives
|
JPH0665280B2
(ja)
|
1987-03-04 |
1994-08-24 |
味の素株式会社 |
タンパクゲル化剤及びそれを用いるタンパクのゲル化方法
|
ES2154627T3
(es)
|
1988-08-24 |
2001-04-16 |
American Cyanamid Co |
Estabilizacion de somatotropinas mediante la modificacion de restos de cisteina utilizando mutagenesis de localizacion dirigida o derivatizacion quimica.
|
US5534617A
(en)
|
1988-10-28 |
1996-07-09 |
Genentech, Inc. |
Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
|
CA2345497A1
(en)
|
1988-10-28 |
1990-04-28 |
Genentech, Inc. |
Growth hormone variants and method for forming growth hormone variants
|
US6780613B1
(en)
|
1988-10-28 |
2004-08-24 |
Genentech, Inc. |
Growth hormone variants
|
ATE193541T1
(de)
|
1989-03-20 |
2000-06-15 |
Gen Hospital Corp |
Insulinotropes hormon
|
US5101018A
(en)
|
1989-06-12 |
1992-03-31 |
International Minerals & Chemical Corp. |
Method for recovering recombinant proteins
|
DE3930696A1
(de)
|
1989-09-14 |
1991-03-28 |
Hoechst Ag |
Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel
|
US5545618A
(en)
|
1990-01-24 |
1996-08-13 |
Buckley; Douglas I. |
GLP-1 analogs useful for diabetes treatment
|
CA2073856C
(en)
|
1990-01-24 |
2002-12-03 |
Douglas I. Buckley |
Glp-1 analogs useful for diabetes treatment
|
US5951972A
(en)
|
1990-05-04 |
1999-09-14 |
American Cyanamid Company |
Stabilization of somatotropins and other proteins by modification of cysteine residues
|
JP2849773B2
(ja)
|
1990-08-27 |
1999-01-27 |
天野製薬株式会社 |
ストレプトミセス属由来のトランスグルタミナーゼの製造法
|
DK220890D0
(da)
|
1990-09-14 |
1990-09-14 |
Ole Buchardt |
Fremgangsmaade til fremstilling af c-terminalt amiderede peptider
|
DE69129154T2
(de)
*
|
1990-12-03 |
1998-08-20 |
Genentech, Inc., South San Francisco, Calif. |
Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
|
JP3267293B2
(ja)
|
1990-12-03 |
2002-03-18 |
ジェネンテク,インコーポレイテッド |
改変された結合性を有する変異タンパク質の豊富化法
|
IT1251895B
(it)
|
1991-09-27 |
1995-05-26 |
Eniricerche Spa |
Mutanti dell'ormone della crescita umano e loro impiego
|
EP0555649B1
(en)
|
1992-01-14 |
2004-12-08 |
Ajinomoto Co., Inc. |
Gene encoding transglutaminase derived from fish
|
CA2489978A1
(en)
|
1992-07-31 |
1994-02-17 |
Genentech, Inc. |
Human growth hormone aqueous formulation
|
ZA936811B
(en)
|
1992-10-28 |
1995-03-15 |
Upjohn Co |
Somatotropin modifications
|
US5359030A
(en)
|
1993-05-10 |
1994-10-25 |
Protein Delivery, Inc. |
Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
|
US5849535A
(en)
|
1995-09-21 |
1998-12-15 |
Genentech, Inc. |
Human growth hormone variants
|
JP3758187B2
(ja)
|
1994-01-28 |
2006-03-22 |
味の素株式会社 |
マガキ由来のトランスグルタミナーゼ
|
JP3720363B2
(ja)
|
1994-08-26 |
2005-11-24 |
ノボザイムス アクティーゼルスカブ |
微生物のトランスグルタミナーゼ、それらの産生及び使用
|
EP0785276A4
(en)
|
1994-09-29 |
2002-01-09 |
Ajinomoto Kk |
MODIFICATION OF A PEPTIDE AND A PROTEIN
|
DE4437604A1
(de)
|
1994-10-21 |
1996-04-25 |
Basf Ag |
Konjugate aus einem Poly- oder Oligopeptid und einer niedermolekularen lipophilen Verbindung
|
CA2208730A1
(en)
|
1995-01-19 |
1996-07-25 |
Novo Nordisk A/S |
Transglutaminases from oomycetes
|
JP3669390B2
(ja)
|
1995-02-09 |
2005-07-06 |
味の素株式会社 |
バチルス属細菌由来のトランスグルタミナーゼ
|
US5869602A
(en)
|
1995-03-17 |
1999-02-09 |
Novo Nordisk A/S |
Peptide derivatives
|
US20020077461A1
(en)
|
1996-04-24 |
2002-06-20 |
Soren Bjorn |
Pharmaceutical formulation
|
US6458924B2
(en)
|
1996-08-30 |
2002-10-01 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
WO1998008872A1
(en)
|
1996-08-30 |
1998-03-05 |
Novo Nordisk A/S |
Glp-2 derivatives
|
US6268343B1
(en)
|
1996-08-30 |
2001-07-31 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
HU227021B1
(en)
|
1996-08-30 |
2010-05-28 |
Novo Nordisk As |
Glp-1 derivatives
|
CN1231675A
(zh)
|
1996-09-26 |
1999-10-13 |
味之素株式会社 |
修饰的生理活性蛋白及含有该蛋白的药物组合物
|
US5985627A
(en)
|
1997-02-28 |
1999-11-16 |
Carlsberg Laboratory |
Modified carboxypeptidase
|
JPH1156378A
(ja)
|
1997-06-11 |
1999-03-02 |
Nippon Chem Res Kk |
変異型ヒト成長ホルモンとその用途
|
KR100706469B1
(ko)
|
1997-06-25 |
2007-04-10 |
어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. |
이황화결합으로 연결된 당단백질 호르몬 유사체, 이의제조방법 및 이의 용도
|
JP2001510033A
(ja)
|
1997-07-14 |
2001-07-31 |
ボルダー バイオテクノロジー, インコーポレイテッド |
成長ホルモンおよび関連タンパク質の誘導体
|
JPH1192499A
(ja)
*
|
1997-09-22 |
1999-04-06 |
Sumitomo Pharmaceut Co Ltd |
ヒト成長ホルモン変異体
|
US6136536A
(en)
|
1997-10-29 |
2000-10-24 |
Genetics Institute, Inc. |
Rapid generation of stable mammalian cell lines producing high levels of recombinant proteins
|
JP2002504527A
(ja)
|
1998-02-27 |
2002-02-12 |
ノボ ノルディスク アクティーゼルスカブ |
部分的に組織化したミセル様凝集物を形成する25%を越えるヘリックス成分を有するglp−2誘導体
|
DE69916811T2
(de)
|
1998-02-27 |
2005-04-14 |
Novo Nordisk A/S |
Glp-1 derivate mit einem helix-gehalt über 25 %, die partiell strukturierte mizellenartige aggregate bilden
|
AU2610599A
(en)
|
1998-02-27 |
1999-09-15 |
Novo Nordisk A/S |
N-terminally truncated glp-1 derivatives
|
EP1062240B1
(en)
|
1998-02-27 |
2010-04-28 |
Novo Nordisk A/S |
N-terminally modified glp-1 derivatives
|
AU3247799A
(en)
|
1998-02-27 |
1999-09-15 |
Novo Nordisk A/S |
Glp-1 derivatives of glp-1 and exendin with protracted profile of action
|
US6656922B2
(en)
|
1998-05-28 |
2003-12-02 |
Mediplex Corporation, Korea |
Oral delivery of macromolecules
|
US6358705B1
(en)
|
1998-07-16 |
2002-03-19 |
Novo Nordisk A/S |
Method of making proteins in transformed yeast cells
|
PT1137667E
(pt)
|
1998-12-07 |
2005-02-28 |
Sod Conseils Rech Applic |
Analogos do glp-1
|
DK1180121T3
(da)
|
1999-05-17 |
2004-03-01 |
Conjuchem Inc |
Langtidsvirkende insulinotrope peptider
|
US6309663B1
(en)
|
1999-08-17 |
2001-10-30 |
Lipocine Inc. |
Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
|
EP1198565A1
(en)
|
1999-07-07 |
2002-04-24 |
Maxygen Aps |
A method for preparing modified polypeptides
|
EP1076066A1
(en)
|
1999-07-12 |
2001-02-14 |
Zealand Pharmaceuticals A/S |
Peptides for lowering blood glucose levels
|
US6528486B1
(en)
|
1999-07-12 |
2003-03-04 |
Zealand Pharma A/S |
Peptide agonists of GLP-1 activity
|
GB2355009A
(en)
|
1999-07-30 |
2001-04-11 |
Univ Glasgow |
Peptides conjugated to bile acids/salts
|
US20040001827A1
(en)
|
2002-06-28 |
2004-01-01 |
Dennis Mark S. |
Serum albumin binding peptides for tumor targeting
|
JP2003519664A
(ja)
|
2000-01-11 |
2003-06-24 |
ノボ ノルディスク アクティーゼルスカブ |
Glp−1誘導体の経上皮送達
|
JP2003521930A
(ja)
|
2000-02-11 |
2003-07-22 |
マキシゲン・エイピーエス |
第VII因子または第VIIa因子様分子
|
DK2216409T3
(en)
|
2000-04-12 |
2015-01-05 |
Novozymes Biopharma Dk As |
Albumin Fusion Proteins
|
IL152804A0
(en)
*
|
2000-05-16 |
2003-06-24 |
Bolder Biotechnology Inc |
Methods for refolding proteins containing free cysteine residues
|
US20020142964A1
(en)
|
2000-11-02 |
2002-10-03 |
Nissen Torben Lauesgaard |
Single-chain polypeptides
|
ES2311560T3
(es)
|
2000-12-07 |
2009-02-16 |
Eli Lilly And Company |
Proteinas de fusion glp-1.
|
US20060183197A1
(en)
|
2001-01-11 |
2006-08-17 |
Andersen Kim V |
Variant growth hormone molecules conjugated with macromolecules compounds
|
JP2004524020A
(ja)
*
|
2001-01-11 |
2004-08-12 |
マキシゲン・エイピーエス |
改良された成長ホルモン分子
|
FR2819810B1
(fr)
|
2001-01-23 |
2004-05-28 |
Pf Medicament |
Peptides non glycosyles derives de la proteine g du vrs et leur utilisation dans un vaccin
|
US6858580B2
(en)
|
2001-06-04 |
2005-02-22 |
Nobex Corporation |
Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
EP1421539B1
(en)
|
2001-06-14 |
2009-10-28 |
The Scripps Research Institute |
Stabilized factor viii with engineered disulfide bonds
|
PT1412384E
(pt)
|
2001-06-28 |
2008-03-28 |
Novo Nordisk As |
Formulação estável de glp-1 modificado
|
WO2003013573A1
(en)
|
2001-08-10 |
2003-02-20 |
Epix Medical, Inc. |
Polypeptide conjugates with extended circulating half-lives
|
AR036711A1
(es)
|
2001-10-05 |
2004-09-29 |
Bayer Corp |
Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
|
EP1444262A2
(en)
|
2001-11-12 |
2004-08-11 |
University of Wales College of Medicine |
Growth hormone variations in humans and their uses
|
AP2004003050A0
(en)
|
2001-11-20 |
2004-06-30 |
Pharmacia Corp |
Chemically modified human growth hormone conjugates
|
JP2003199569A
(ja)
|
2001-12-17 |
2003-07-15 |
Food Industry Research & Development Inst |
ストレプトベルティシリウム・ラダカヌムのトランスグルタミナーゼ遺伝子及び該遺伝子によってコードされるトランスグルタミナーゼ
|
FR2836382B1
(fr)
|
2002-02-28 |
2004-08-13 |
Biomerieux Sa |
Nouveaux agents de couplages, leurs conjugues, ainsi que l'utilisation de ces conjugues dans des methodes de diagnostic
|
WO2004065621A1
(en)
|
2002-03-01 |
2004-08-05 |
Dyax Corp. |
Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
|
IL164266A0
(en)
|
2002-04-10 |
2005-12-18 |
Lilly Co Eli |
Treatment of gastroparesis
|
CA2483478A1
(en)
|
2002-04-30 |
2003-11-13 |
Maxygen Holdings Ltd. |
Factor vii or viia polypeptide variants
|
CA2498319A1
(en)
|
2002-09-09 |
2004-03-18 |
Nautilus Biotech |
Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
|
DE602004025205D1
(de)
|
2003-02-19 |
2010-03-11 |
Ipsen Pharma |
Glp-1-analoga
|
CA2523408A1
(en)
|
2003-05-09 |
2004-11-18 |
Novo Nordisk A\S |
Peptides for use in treating obesity
|
EP1653996A2
(en)
|
2003-08-08 |
2006-05-10 |
Novo Nordisk Health Care AG |
Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
|
CN100444898C
(zh)
|
2003-09-19 |
2008-12-24 |
诺沃挪第克公司 |
治疗肽的清蛋白结合型衍生物
|
EP1667724A2
(en)
|
2003-09-19 |
2006-06-14 |
Novo Nordisk A/S |
Albumin-binding derivatives of therapeutic peptides
|
RU2401276C2
(ru)
|
2003-09-19 |
2010-10-10 |
Ново Нордиск А/С |
Производные глюкагон-подобного пептида-1 (glp-1)
|
EP2932981B1
(en)
|
2003-09-19 |
2021-06-16 |
Novo Nordisk A/S |
Albumin-binding derivatives of GLP-1
|
JP2007508250A
(ja)
|
2003-10-10 |
2007-04-05 |
ノボ ノルディスク アクティーゼルスカブ |
持続性放出製剤における長期作用性分子
|
ATE461217T1
(de)
|
2003-12-18 |
2010-04-15 |
Novo Nordisk As |
Glp-1-verbindungen
|
AU2004298425A1
(en)
|
2003-12-18 |
2005-06-30 |
Novo Nordisk A/S |
Novel GLP-1 analogues linked to albumin-like agents
|
MXPA06008209A
(es)
|
2004-01-21 |
2006-08-31 |
Novo Nordisk As |
Conjugacion de peptidos mediada por transglutaminasa.
|
SG135176A1
(en)
|
2004-02-02 |
2007-09-28 |
Ambrx Inc |
Modified human four helical bundle polypeptides and their uses
|
EA010626B1
(ru)
|
2004-04-07 |
2008-10-30 |
Арес Трейдинг С.А. |
Жидкий состав гормона роста
|
US7906137B2
(en)
|
2004-05-21 |
2011-03-15 |
Mediplex Corporation, Korea |
Delivery agents for enhancing mucosal absorption of therapeutic agents
|
WO2006005667A2
(en)
|
2004-07-08 |
2006-01-19 |
Novo Nordisk A/S |
Polypeptide protracting tags comprising a tetrazole moiety
|
US20090176967A1
(en)
|
2004-08-02 |
2009-07-09 |
Novo Nordisk Healthcare A/G |
Conjugation of FVII
|
JP2008515856A
(ja)
|
2004-10-07 |
2008-05-15 |
ノボ ノルディスク アクティーゼルスカブ |
遅延性glp−1化合物
|
US7998930B2
(en)
|
2004-11-04 |
2011-08-16 |
Hanall Biopharma Co., Ltd. |
Modified growth hormones
|
AU2005322019B2
(en)
|
2004-12-22 |
2010-08-26 |
Ambrx, Inc. |
Formulations of human growth hormone comprising a non-naturally encoded amino acid
|
TWI362392B
(en)
|
2005-03-18 |
2012-04-21 |
Novo Nordisk As |
Acylated glp-1 compounds
|
EP1863537A2
(en)
|
2005-03-18 |
2007-12-12 |
Novo Nordisk A/S |
Dimeric peptide agonists of the glp-1 receptor
|
CN101128214A
(zh)
|
2005-03-18 |
2008-02-20 |
诺和诺德公司 |
长效glp-1化合物
|
ES2553160T3
(es)
|
2005-06-17 |
2015-12-04 |
Novo Nordisk Health Care Ag |
Reducción y derivatización selectivas de proteínas Factor VII transformadas por ingeniería que comprenden al menos una cisteína no nativa
|
CN101263225A
(zh)
|
2005-08-18 |
2008-09-10 |
诺沃-诺迪斯克保健股份有限公司 |
改进转谷氨酰胺酶的底物特异性
|
EP1928906A2
(en)
|
2005-08-30 |
2008-06-11 |
Novo Nordisk Health Care AG |
Liquid formulations of pegylated growth hormone
|
CN1939534B
(zh)
|
2005-09-27 |
2010-12-01 |
长春金赛药业股份有限公司 |
含有人生长激素或人粒细胞巨噬细胞刺激因子的用于治疗损伤和溃疡的外用制剂
|
AU2007215566A1
(en)
*
|
2006-01-19 |
2007-08-23 |
Ambrx, Inc. |
Non-natural amino acid polypeptides having modulated immunogenicity
|
WO2007093594A1
(en)
|
2006-02-14 |
2007-08-23 |
Novo Nordisk Health Care Ag |
Coupling of polypeptides at the c-terminus
|
RU2009103198A
(ru)
|
2006-07-07 |
2010-08-20 |
Ново Нордиск Хелс Кеа Аг (Ch) |
Новые белковые конъюгаты и способы их получения
|
US9873667B2
(en)
|
2006-07-27 |
2018-01-23 |
Emisphere Technologies Inc. |
Arylsulfanyl compounds and compositions for delivering active agents
|
US20090318349A1
(en)
|
2006-08-18 |
2009-12-24 |
Novo Nordisk Health Care Ag |
Transglutaminase variants with improved specificity
|
WO2008027854A2
(en)
|
2006-08-31 |
2008-03-06 |
Novartis Ag |
Pharmaceutical compositions comprising hgh for oral delivery
|
US20080095837A1
(en)
|
2006-08-31 |
2008-04-24 |
Emisphere Technologies, Inc. |
Human growth hormone formulations
|
JP5390404B2
(ja)
|
2007-02-16 |
2014-01-15 |
エミスフェアー・テクノロジーズ・インク |
活性薬剤を送達するための環状部分を有する化合物及び組成物
|
WO2008112836A2
(en)
|
2007-03-15 |
2008-09-18 |
Novartis Ag |
Pharmaceutical composition comprising human growth hormon
|
US20100261637A1
(en)
|
2007-09-05 |
2010-10-14 |
Novo Nordisk A/S |
Peptides derivatized with a-b-c-d- and their therapeutical use
|
CA2733200A1
(en)
|
2008-08-06 |
2010-02-11 |
Novo Nordisk Health Care Ag |
Conjugated proteins with prolonged in vivo efficacy
|
EP2324056A1
(en)
|
2008-09-09 |
2011-05-25 |
Novo Nordisk Health Care AG |
Growth hormone conjugate with increased stability
|
JP5591243B2
(ja)
|
2008-09-12 |
2014-09-17 |
ノボ・ノルデイスク・エー/エス |
ペプチド又はタンパク質のアシル化の方法
|
MX2011007736A
(es)
|
2009-01-22 |
2011-09-06 |
Novo Nordisk Healthcare Ag |
Compuestos de hormona del crecimiento estables.
|
EP2398822B1
(en)
|
2009-02-19 |
2013-01-02 |
Novo Nordisk A/S |
Modification of factor viii
|
CN102612376A
(zh)
|
2009-08-06 |
2012-07-25 |
诺沃-诺迪斯克保健股份有限公司 |
具有延长的体内功效的生长激素
|
SI2525834T1
(sl)
|
2010-01-22 |
2019-10-30 |
Novo Nordisk Healthcare Ag |
Rastni hormoni s podaljšano in vivo učinkovitostjo
|
US9211342B2
(en)
|
2010-01-22 |
2015-12-15 |
Novo Nordisk Healthcare Ag |
Stable growth hormone compounds resistant to proteolytic degradation
|
EP2536434B1
(en)
|
2010-02-16 |
2016-04-20 |
Novo Nordisk A/S |
Purification method
|